Evidence map›Paper›PMID 43005616›Full record

ReviewFrontiers in immunology2026

The obesity-neuroinflammation-cancer axis: neuroimmune remodeling and therapeutic opportunities.

Nan Yang, Wei Zhang, Yinsheng Zhong, Zhenghua Ding

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nan Yang *Department of General Surgery, Xiangyang No 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Wei Zhang *Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Yinsheng ZhongDepartment of General Surgery, Xiangyang No 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Zhenghua DingDepartment of General Surgery, Xiangyang No 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.

Funding

Faculty Development Grants of Xiangyang No. 1 People's Hospital Affiliated to Hubei University of MedicineHubei Provincial Natural Science Foundation of China
6 · The paper itself

Abstract

Obesity is a chronic metabolic and inflammatory disorder associated with increased risk and poorer outcomes in multiple malignancies. Although adipose inflammation, insulin resistance, and altered adipokine signaling are established links between obesity and cancer, these mechanisms do not fully explain how systemic metabolic stress is translated into persistent changes in tissue immunity and tumor behavior. This narrative Review proposes the obesity-neuroinflammation-cancer axis as an integrative framework in which obesity-associated metabolic and inflammatory signals perturb central and peripheral neural homeostasis, while neuroinflammation, neural remodeling, and neuroendocrine signaling reshape the tumor microenvironment through reciprocal interactions among nerves, immune cells, stromal cells, and cancer cells. We focus on obesity-induced neuroinflammation, tumor neuroimmune remodeling, and neuroimmunometabolic feedback, highlighting sympathetic signaling, leptin-JAK/STAT3, NF-κB, inflammasome pathways, and metabolic reprogramming. We further evaluate therapeutic opportunities involving metabolic, inflammatory, and adrenergic interventions, including their combination with immune checkpoint blockade, while emphasizing inconsistent clinical evidence and the need for composite biomarkers. This framework is intended as a testable synthesis rather than a universally established causal pathway and identifies cancer-type-specific neuroimmune circuits as a priority for future translational research.

Indexed as

NeoplasmsNeuroimmunomodulationNeuroinflammatory DiseasesObesityAnimalsHumansInflammationMetabolic ReprogrammingSignal TransductionTumor Microenvironmentcancerimmunometabolismneuroimmune crosstalkneuroinflammationobesitysympathetic nervous systemtumor microenvironment

Identifiers

PMID43005616
PMCPMC13746125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.